Catlin E A, MacLaughlin D T, Donahoe P K
Pediatric Surgical Research Laboratory, Massachusetts General Hospital, Boston 02114.
Microsc Res Tech. 1993 Jun 1;25(2):121-33. doi: 10.1002/jemt.1070250205.
MIS, as a differentiate and antiproliferative agent, is precisely regulated, for example, at the transcriptional level by such transacting factors as SRY, and posttranslationally by testosterone. Processing of MIS most likely requires an as yet unknown in vivo protease which probably serves to control cleavage of MIS and hence its activation at specific sites wherein a localized program of cell death is initiated via a receptor mediated event. Progress has been made in understanding the molecular domains of MIS; current efforts are focused on characterizing the wild type MIS receptor as well as cloning and expressing the MIS receptor. We need now to understand how to target and efficiently activate MIS at its projected site of action. We must focus, after structural analysis of its receptor, on elucidating the MIS initiated intracellular signals which result in localized cell inhibition. Understanding of these mechanisms will permit design of antitumor agents and therapeutic strategies. Similarly, understanding regulation of MIS expression may lead to therapeutic induction of expression in those states where depressed expression is associated with tumorigenesis, sexual ambiguity, or infertility.
苗勒管抑制物质(MIS)作为一种分化和抗增殖因子,受到精确调控,例如在转录水平上受SRY等反式作用因子调控,在翻译后受睾酮调控。MIS的加工过程很可能需要一种尚未明确的体内蛋白酶,该蛋白酶可能用于控制MIS的切割,从而在特定部位激活MIS,在这些部位通过受体介导的事件启动局部细胞死亡程序。在理解MIS的分子结构域方面已取得进展;目前的工作重点是表征野生型MIS受体以及克隆和表达MIS受体。我们现在需要了解如何在其预计的作用部位靶向并有效激活MIS。在对其受体进行结构分析之后,我们必须专注于阐明由MIS引发的导致局部细胞抑制的细胞内信号。对这些机制的理解将有助于设计抗肿瘤药物和治疗策略。同样,了解MIS表达的调控可能会在那些MIS表达降低与肿瘤发生、性器官发育异常或不育相关的状态下实现对其表达的治疗性诱导。